

PRAZosin for patients with Obsessive Compulsive disorder

Submission date 21/03/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 24/05/2011	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 29/12/2020	Condition category Mental and Behavioural Disorders	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Damiaan Denys

Contact details
Academic Medical Centre
Psychiatry
Meibergdreef 9
Amsterdam
Netherlands
1105 AZ
+31 (0)20 891 0602
d.denys@amc.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
08/063

Study information

Scientific Title

PRAZosin in combination with a serotonin reuptake Inhibitor for patients with Obsessive Compulsive disorder: an open label study

Acronym

PRAZOC

Study objectives

It is hypothesised that prazosin in combination with a Serotonin Reuptake Inhibitor (SRI) might possess an anti-obsessive compulsive disorder (OCD) modulating effect by raising dopamine (DA) levels in the synaptic cleft in the prefrontal cortex and inhibiting extracellular DA concentrations in the nucleus accumbens

Ethics approval required

Old ethics approval format

Ethics approval(s)

Medical Ethics Committee of the Academic Medical Centre Amsterdam in December 2008

Study design

Open label cohort study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Obsessive compulsive disorder

Interventions

1. Prazosin 5-20 mg/day for 12 weeks in addition to ongoing treatment with SRI
2. The total duration of follow up will be 12 weeks (i.e. no follow up beyond the end of the intervention)

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Prazosin

Primary outcome measure

1. Decrease in Y-BOCS score
2. Measured at baseline, 2, 4, 6, 8, 10 and 12 weeks

Secondary outcome measures

1. Clinical Global Impression (CGI)
2. Hamilton Depression Rating Scale (HDRS)
3. All outcomes measured at baseline, 2, 4, 6, 8, 10 and 12 weeks

Overall study start date

01/03/2010

Completion date

01/08/2010

Eligibility**Key inclusion criteria**

1. All patients meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV) criteria for obsessive-compulsive disorder
2. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score (two consecutive measurements within two weeks)
 - 2.1. > 16 if obsessions and compulsions
 - 2.2. > 10 if only obsessions
 - 2.3. > 10 if only compulsions
3. Therapy resistance, defined as not having responded to at least 1 previous treatment with an SRI at maximum dose and duration
4. Male and female, aged between 18-70 years
5. Female patients of childbearing potential must have a negative pregnancy test and use a reliable method of contraception
6. Written informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Upper age limit

70 Years

Sex

Both

Target number of participants

10

Key exclusion criteria

1. Presence of any of the following DSM IV conditions:
 - 1.1. Major depression (with a Hamilton Depression Rating Scale [HDRS] > 15, [17 item])
 - 1.2. Bipolar disorder
 - 1.3. Schizophrenia or any other psychotic condition, tic disorder, substance related disorder during the past 6 months
 - 1.4. Epilepsy
 - 1.5. Structural central nervous system (CNS) disorder or stroke within the last year
2. Evidence of clinically significant and unstable cardiovascular, gastro-intestinal, pulmonary, renal, hepatic, endocrine or haematological disorders, glaucoma, myocardial infarction within the past year, or micturition abnormalities
3. Patients at risk for suicide
4. Multiple serious drug allergies or known allergy for the trial compounds
5. Use of antipsychotics during 6 months before the screening visit
6. Use of any other psychotropic drug during 6 months before the screening visit
7. Cognitive and behavioural treatment 3 months prior to the screening visit
8. Use of drugs that interact with prazosin: diuretic or other antihypertensive agents (which can cause an additive hypotensive effect)
9. Regular use of alcohol

Date of first enrolment

01/03/2010

Date of final enrolment

01/08/2010

Locations**Countries of recruitment**

Netherlands

Study participating centre

Academic Medical Centre

Amsterdam

Netherlands

1105 AZ

Sponsor information

Organisation

Academic Medical Centre (AMC) (Netherlands)

Sponsor details

Psychiatry Department
Meibergdreef 9
Amsterdam
Netherlands
1105 AZ
+31 (0)20 891 3602
m.figee@amc.nl

Sponsor type

Hospital/treatment centre

Website

<http://www.amcpsychiatrie.nl/>

ROR

<https://ror.org/03t4gr691>

Funder(s)**Funder type**

Hospital/treatment centre

Funder Name

Academic Medical Centre (AMC) (Netherlands)

Results and Publications**Publication and dissemination plan**

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/02/2016	29/12/2020	Yes	No

